HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

This study is looking at whether blood-based biomarkers and quantitative MRI imaging can predict how well the liver tolerates and responds to radiation therapy in people with liver cancer (hepatocellular carcinoma, cholangiocarcinoma) or cancer that has spread to the liver. A subset of participants will also undergo a special liver function test called HepQuant. The goal is to find better ways to monitor liver health before, during, and after radiation treatment. **You may be eligible if...** - You are over 18 years old - You have liver cancer or a cancer that has spread to the liver (hepatic metastases) and are receiving radiation therapy as part of your care - You are able to provide informed consent and complete the required follow-up visits - Prior liver treatments (surgery, TACE, ablation, chemotherapy, or radiation) are allowed **You may NOT be eligible if...** - You are unable to undergo MRI (due to metal implants, claustrophobia, or other contraindications) - You are too unwell to complete the study requirements - You do not consent to blood draws or imaging for research purposes - For the HepQuant sub-study: you do not meet the additional criteria required for that specific test Talk to your doctor to see if this trial is right for you.